Crystal entecavir, crystal entecavir formulation and methods for the preparation thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9408849
APP PUB NO 20140220120A1
SERIAL NO

14246029

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection comprising crystalline entecavir as the pharmaceutically active ingredient and one or more pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have improved stability compared to that of amorphous entecavir under the conditions of light, high temperature and high humidity.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ZHEJIANG MEDICINE CO LTD XINCHANG PHARMACEUTICAL FACTORYSHAOXING ZHEJIANG 312500

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Tian, Zhike Huancheng Donglu, CN 2 0
Ye, Weidong Huancheng Donglu, CN 15 27
Yi, Deping Huancheng Donglu, CN 2 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 9, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00